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 Abstract 
Diabetes mellitus is a disease in which the body loses its ability to provide tight regulation and maintain a dynamic 
interaction between the tissue sensitivity and insulin secretion by β cells. The impact of this dysfunctional mechanism is 
uncontrolled blood glucose levels that lead to hyperglycemia condition. Highly reactive free radicals have a strong 
involvement in the pathogenesis of diabetes mellitus, where one of its forming process may be triggered by 
hyperglycemia condition. Patients with diabetes mellitus itself vulnerable to endothelial dysfunction, which is caused by 
a decrease in circulating endothelial progenitor cells, and also a decrease in chemokines which play a role in affecting 
the activities of these cells. Hyperglycemia condition and free radical activity is a major cause of these endothelial 
progenitor cells dysfunction.The purpose of this study was to determine the role of VipAlbumin®, a supplement derived 
from Channa striatus albumin extracts in inhibiting the action of free radicals that are formed due to hyperglycemia 
condition, which can affect the increase in endothelial progenitor cells relative amount. This study used BALB/C mice 
that induced to undergo diabetes mellitus through streptozotocin injection intraperitoneally at 5-day old. Mice who 
have reached 4 week old and positive to diabetes mellitus (blood glucose levels > 200 mg.dl
-1
) will be administered with 
VipAlbumin® orally for 14 days. VipAlbumin® dosage was divided into 4 groups: positive control (without VipAlbumin®); 
1
st
 dose (0.01664 mg.gr
-1
 BW); 2
nd
 dose (0.416 mg.gr
-1
 BW); 3
rd
 dose (10.4 mg.gr
-1
 BW). The last step was flow 
cytometric analysis to determine the development of endothelial progenitor cells relative amount, which isolated from 
bone marrow. The variables measured in this study were the relative amount of CD34
+
 and SDF-1. Based to flow 
cytometric analysis, mice with VipAlbumin® administration did not show any significant improvement in CD34 relative 
amount when compared to the positive control. Relative amount of Chemokine SDF-1 itself, although only occur at the 
3
rd
 dose of VipAlbumin® treatment, has increased and significantly different from the positive control.  
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INTRODUCTION 
CD34 is a transmembrane glycoprotein sized 
115-kD which is strongly expressed on progenitor 
/hematopoietic stem cell (HSPC), and progress-
ively decreased when HSPCs differentiate [1,2]. 
CD34 is a wide used marker to detect hemato-
poietic progenitor in human. Several researches 
show that antigen CD34 has signal with 
transduction capacity and is involved in cell 
adhesion, which resulting polymerization of actin 
and homotypic adhesion on cells of CD34+ and 
KG1a [3-7]. Circulation of immature cells derived 
from bone marrow, one of which is CD34+ cells, 
contributes in holding vascular homeostasis and 
repair, and play an important role in maintaining 
vascular endothelial function [8].  
The amount of CD34+ cells, as the part of 
endothelial progenitor cells, are lower in diabetic 
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patients compare to those with normal glucose 
tolerance [9]. This leads to the reinforcement of 
the disease in triggering the endothelial dys-
function and the other forms of complication. 
The high-level of blood glucose and free 
radicals activity on diabetic patients also can 
influence the reduction of SDF-1, a chemokine 
functioned to stimulate the mobilization of  
endothelial progenitor cells from bone marrow 
[10]. Stromal cell-derived factor-1 (SDF-1) or 
CXCL12 is a chemokine for CXC subfamily which is 
generally characterized as the pre-B cell stimu-
lation factor and clonized from bone marrow 
cells supernatant [11]. SDF-1 is chemotactic 
factor for T cells, monocyte, pre-B cell, dendritic, 
and hematopoietic progenitor cells, and also 
functioned to support proliferation of B and 
CD34+ progenitor cells. SDF-1 gave its effect by 
binding with CXCR, a member of G protein-
coupled receptor superfamily [14,15]. 
Responding to ischemia, SDF-1 regulation is 
usually increased, and through its binding with 
CXCR4, will stimulate the bone marrow to release 
EPC (one of them is CD34
+ 
cells) which will later 
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be recruited in ischemic area [10]. In diabetic 
animal, the deformed response of SDF-1 to 
ischemia correlates with the decline of 
progenitor cells release from bone marrow and 
will cause post-ischemic angiogenesis deforma-
tion [16].   
To figure out the effect of blood glucose level 
increase towards cells development which 
expresses CD34 and SDF-1, mice models of 
diabetes mellitus are used. The mice are injected 
by streptozotocin, a molecule of 2-Deoxy-2-
({[methyl (nitroso) amino] carbonyl} amino) -β-D 
glucopyranose, that produce selective toxic 
toward β cells and inducting diabetes mellitus in 
most of laboratory animals. High dose of β cells 
toxin such as streptozotocin and alloxan 
inducting insulin deficiency and type 1 diabetes 
with ketosis. But a precise dose calculation would 
partially destruct β celss mass and conduct mild 
insulin resistance that characterize type 2 
diabetes [17]. 
The increase of blood sugar level through the 
injection of streptozotocin would trigger highly 
reactive radicals formation. In this research, 
VipAlbumin®, a supplement which extracted 
from Channa striatus, is used to obstruct free 
radicals impact on the endhothelial progenitor 
cells activity. Several researches show that the 
snakehead murrell (Channa striatus) has positive 
effect as anti-inflammatory agent [18] reviewed 
from the high arachidonic acids level and 
important amino acids such as aspartic, glycine, 
and glutamic acid [19]. It also becomes the key 
factor in polypeptide formation which takes role 
in growth and wound healing [20,21]. The other 
functions are due to substance conductor, osmo-
tic pressure regulator, platelets and anti-
thrombotic formation hindrance, increase cells 
permeability, and as antioxidant [22,23]. 
 
MATERIALS AND METHODS 
This research was conducted from November 
2014 to May 2015 in Laboratory of Animal 
Physiology, Department of Biology, Faculty of 
Mathematics and Natural Sciences, University of 
Brawijaya. 
 
Research design 
The research was categorized into experi-
mental research, in which the researcher 
intentionally manipulating the treatment to see 
the emerging effect. This research used in vivo 
procedure. There were 5 different treatment 
groups, i.e. negative control (healthy mice 
without streptozotocin injection and 
VipAlbumin® administration), positive control 
(diabetes mellitus model mice without 
VipAlbumin® administration), and diabetes 
mellitus model mice with VipAlbumin® 
administration on 3 different doses. Each 
treatment were divided into 5 repetition. 
 
In vivo Procedure 
Diabetes mellitus model-mice induction through 
streptozotocin injection 
Healthy mice were induced to have diabetes 
mellitus through streptozotocin injection intra-
peritoneally at a dose of 100 mg.kg-1 BW in the 
age of 5 days. Each mice in this research was 
assumed to weigh 2.5 g, thus, the proper dose of 
streptozotocin is 50 µl. This amount derived from 
the mixture of 0.005 g of streptozotocin powder 
with 1 ml of citrate buffer. Successfully injected 
mice were then nurtured in sterile environment. 
The measurement of blood glucose level was 
conducted when the mice were reaching 4 week-
old, by using glucometer. Mice was diagnosed 
undergo diabetes mellitus if the blood glucose 
levels were more than 200 mg.dl-1. 
 
VipAlbumin® administration on various doses 
Oral administration of VipAlbumin® was done 
daily for 14 days to the diabetic mice. This 
administration were divided into 3 treatment 
doses: 0.01664 mg.g
-1
 BW (dose 1); 0.416 mg.g
-1
 
BW (dose 2); 10.4 mg.g-1 BW (dose 3). These 
three doses were derived from the albumin dose 
conversion for 1 kg of human BW i.e. 33.3 mg.kg-1 
with the assumption that the normal weight of 
adults was 60 kg. In order to figure out 
VipAlbumin® effect in decreasing blood glucose 
level, the measurement was done regularly in 
every 3 days.  
 
Cell isolation from bone marrow 
Mice were dislocated and dissected. 
Afterward, the femur and tibia part of the mice 
were flushed with PBS by using 1 ml spuit at one 
end. The obtained suspension is later put into 
propylene tube and centrifuged on 2500 rpm, 
10oC temperature, for 5 minutes. The pellet 
formed was then resuspended with 1 ml PBS. The 
resuspension then taken5 µl, put in microtube, 
and added with 95 µl evans blue. Pipetting is 
done for homogenization. The amount of 
successfully isolated cells was later counted with 
haemocytometer under microscope. 
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Antibody staining and Flowcytometric analysis 
The staining process were divided into two 
phases based on the antibody type used. The first 
phase was extracellular antibody staining. 250 µl 
cell suspension isolated from bone marrow was 
put into microtube and centrifuged on 2500 rpm 
speed, 10oC temperature, for 5 minutes. 
Supernatant was eliminated and the pellet was 
added with 1 µl antibody which has being 
liquified with 50µl PBS dan 10% FBS. The 
suspension was later incubated in 4oC ice box for 
20 minutes. The staining combination used was 
FITC-conjugated rat anti-mouse CD34. 
The second phase was intracellular antibody 
staining. After conduct the procedure of 
extracellular antibody staining, cells were then 
given with 100 µl fixative solution cytofix/ 
cytoperm and incubated 20 minutes in ice box. 
Mixed the cells with 500 µl washperm in order to 
clean the fixative solution remains. The 
suspension was re-centrifuged on 2500 rpm, 10oC 
temperature, for 5 minutes, whereas the pellet 
was then stained with intracellular antibody and 
incubated for 20 minutes in ice box. The staining 
combination used is PE/Cy5-conjugated SDF-1. 
The cells which were incubated by antibody 
staining is added with 300-500 µl PBS, and then 
moved into cuvette and being operated in 
flowcytometry machine. 
 
Flowcytometric Data Analysis 
The data obtained from flowcytometrythen 
analyzed with BD Cellquest Pro™ software, and 
continued with the statistical analysis using SPSS 
version 16 for Windows. The statistical analysis 
used was one way ANOVA parametric analysis 
with p = 0,05%, followed by Tukey test. 
 
RESULT AND DISCUSSION 
Comparison of blood glucose levels on each 
treatment 
The comparison of mice blood glucose levels 
on each treatment was measured regularly once 
in 3 days, for 15 days (Fig. 1). The positive control 
group (diabetic mice without VipAlbumin® 
administration) has significantly higher blood 
glucose levels than other treatments. Although it 
is not as high as the positive control, 1st dose 
(0.01664 mg.g-1 BW) of VipAlbumin® also has an 
increase in blood glucose level along with the 
age. Both 2nd (0,.416 mg.g-1 BW) and 3rddose 
(10.4 mg.g-1 BW) of VipAlbumin® tend to have 
fluctuated blood glucose levels, which was able 
to increase or decrease depends on measu-
rement days. However, the blood glucose levels 
from both treatments were significantly lower 
than positive control. The negative control has 
the lowest sugar blood level compared with the 
other treatments. 
 
Flow cytometric analysis of CD34+ relative 
amount 
We figured out that the relative amount of 
CD34+ cells in diabetic mice hasa significant 
decrease compared with the normal mice (Fig. 2). 
The healing effort through VipAlbumin® admi-
nistration has not given a notable change yet, 
whereas none of the three doses of VipAlbumin® 
treatment can increase CD34 expression and 
significantly different from the positive control 
(Fig. 3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.The Comparison of Blood Glucose Levels on Each Treatment 
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Figure2.The Profile of CD34+ through flow cytrometric analysis 
(a) negative control, (b) positive control, (c) VipAlbumin® 1st dose, (d) VipAlbumin® 2nd dose, (e) VipAlbumin® 3rd dose
 
 
 
 
            
     
 
 
 
 
 
 
 
 
 
Figure 3. The comparison of CD34 relative amount on each treatment 
 
It has been elucidated that diabetic patients 
experiencing the decrease of circulated 
progenitor. Although without complication, the 
amount of progenitor cells majority on diabetic 
patients still significantly lower than healthy 
control. The endothelial progenitor cells 
reduction can also be happened on patients with 
high blood glucose level and HbA1c (glycated 
hemoglobin) [24]. The previous research 
mentioned that the amount of CD34+, one type 
of the immature cell which was circulated in 
blood and becomes the part of endothelial 
progenitor cells (EPC), was lower in diabetic 
b 
a a 
a a 
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patients compared with subjects having normal 
tolerance of blood glucose level [9]. 
The increase of blood glucose level (hyper-
glycemia) became the main factorto affecting 
endothelial dysfunction, which was the first 
criterion of atherosclerosis pathogenesis [25,26]. 
Endothelial dysfunction takes important role in 
the development of atherosclerosis, and the 
circulation of endothelial progenitor cells derived 
from the bone marrow participating in the repair 
of vascular endothelial cells and defending the 
function of endothelial. On the patients with 
diabetes, it is reported that there was decreasing 
amount and dysfunction of circulated EPC, 
contributing to the diabetic microvascular 
complication [27].  
Various research using animal model showed 
that the circulated EPC cells contribute to re-
endothelialization and/or neovascularzation the-
rapy [28,29]. Several evidence indicates that 
various chemokin, cytokine, growth factor and 
their specific receptors can regulate the 
mobilization and recruitment of EPC from the 
bone marrow to the peripherals area, and in the 
process of proliferation and differentiation 
[30,31]. The chemokine (motif C-X-C) receptor 4 
(CXCR4), receptor for SDF-1, play important role 
in the mobilization of cells from bone marrow 
and also in regulating the mobilization and 
recruitment of EPC [32-36]. 
One alternative way to prevent complication 
caused by hyperglycemia condition and the 
formation of free radicals is through induction of 
endothelial progenitor cells activation; in which 
this research using VipAlbumin®administration to 
conduct that process. Although the result shows 
that there was no significant increase in relative 
amount of CD34 compared with the positive 
control, it does not eliminate the potential 
function of albumin. Albumin functioned as the 
antioxidant to obstruct the free radicals ROS/NOS 
movement, maintaining the extracellular redox 
equilibrium, and playing role in the transport-
ation process of various molecules such as fatty 
acid, nitric oxide, hemin, and drugs [37,38]. Some 
other researches show that in culture condition, 
albumin can be used as the inhibitor of apoptosis 
process for macrophages, neutrophil, lympho-
cyte, and endhotelial cells [39-42]. In primary 
structure form, albumin contains 34 cysteine 
residues contributing with 17 disulfide bridges to 
form whole tertiary structure with one free 
cysteine residue (Cys34) which plays important 
role in various functions of albumin mentioned 
before. This very active residue that containing 
80% (500 µmol.L-1) total thiol in plasma is the 
primary scavenger of reactive oxygen and 
nitrogen in plasma [43]. 
Another strategy also proposed to improve 
the healthy condition from diabetic patients with 
hyperglycemia by using propolis  treatment [44]. 
This material is known to contain high-level of 
nutrient factor such as vitamins, polyphenols, 
and amino acids, that expected to improve 
insulin sensitvity and suppress the action of 
inflammatory molecules. This suppression acti-
vity had a high relationship with the ability of T 
regulatorycells (especially on CD4+CD25+ popula-
tion), while the increase number of this cells can 
induced by propolis intake. Highly reactive T cells 
could induce insulin resistance by its pro-
inflammatory action, but T regulatory cells can 
prevent this effect by producing IL-10 and TGF-β. 
This cells can also prevents inflammatory 
condition being wide-spread, by reversing the 
activated memory T cells become naive type [45]. 
 
Flow cytometric analysis of SDF-1 relative 
amount 
Flow cytometric data analysis shows that 
relative amount of SDF-1 on diabetic mice was 
significantly decrease compared to the normal 
control (Fig. 4). Two given doses of VipAlbumin® 
i.e. 1st dose (0.01664 mg.g-1 BW) and 2nd dose 
(0.416 mg.g
-1
 BW) did not show meaningful 
increase of SDF-1 expression. The significant 
increase com-pared with the positive control only 
occured in the 3rd dose (10.4 mg.g-1 BW) of 
VipAlbumin®, although the relative amount has 
not yet reached the normal condition (Fig. 5).  
It was reported that diabetic patients will 
experience the decrease of SDF-1, a chemokine 
that stimulates the endothelial progenitor cells 
mobilization (EPC) derived from the bone 
marrow [10]. The decreased ability of EPC 
mobilization from the bone marrow becomes 
one of the mechanism resulting the low amount 
of circulated EPC [28,36]. It has been known that 
SDF-1 and the expression of its receptor (CXCR4) 
play an important role in the regulation of 
mobilization and recruitment of progenitor cells, 
so that the reduction of the molecules estimated 
to be the cause of low amount of circulated EPC 
[32,34,36]. The cells expressing CXCR4 correlates 
positively with the progenitor cells amount on 
normal individual, while on diabetic patients, 
there is no correlation. Other research indicated 
that there is significant decrease of CXCR4 
expression in PBMC of type 2 diabetic patients 
[24]. 
 J.Exp. Life Sci. Vol. 5 No. 1, 2015  ISSN. 2087-2852 
  E-ISSN. 2338-1655 
15 VipAlbumin® Effect in CD34 and SDF-1 Mobilization in Streptozotocin-induced  
diabetic mice (Pradana et al.) 
 
Figure 4.The Profile of SDF-1 through flow cytrometric analysis;  
(a) negative control, (b) positive control, (c) VipAlbumin® 1st dose, (d) VipAlbumin® 2nd dose, (e) VipAlbumin® 3rddose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. The comparison of SDF-1 relative amount on each treatment
The decrease of circulated EPC amount is 
affected by the low ability of EPC cells in 
responding to SDF-1 [36]. It was also reported 
that on diabetic patients, there is decrease in 
ability of CD34+ cells in migrating, which is 
affected by the disability in responding the SDF-1 
performance [46]. The genotype of SDF-1 can 
influences insulin in mobilizing mature progenitor 
cells on type 2 diabetic patients [47]. 
 
CONCLUSION 
In this research, the administration of three 
doses of VipAlbumin® were not capable to 
increase CD34 relative amount, one of 
c 
a a 
a 
b 
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endothelial progenitor cells marker derived from 
bone marrow. 1st and 2nd dose of VipAlbumin® 
also has no ability to stimulate the development 
of SDF-1 relative amount. The development of 
this molecule only occur at the 3rd dose of 
VipAlbumin® (10.4 mg.g-1 BW), and was 
significantly different from positive control. 
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